Integrated Filing — IndAS



General information about company

Scrip Code 532523
NSE Symbol BIOCON
MSEI Symbol NOTLISTED
ISIN INE376G01013
Name of company BIOCON LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 04-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 26-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 04-11-2026   11:20:00
End date and time of board meeting 04-11-2026   13:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 11-02-2026
Indicate Company website link for updated RPT policy of the Company https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default on Loans and Debt Securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 63,050.00 1,25,500.00
Other income 9,070.00 15,550.00
Total income 72,120.00 1,41,050.00
2 Expenses
(a) Cost of materials consumed 29,950.00 56,140.00
(b) Purchases of stock-in-trade 0.00 650.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,900.00) (80.00)
(d) Employee benefit expense 11,710.00 25,020.00
(e) Finance costs 2,190.00 3,920.00
(f) Depreciation, depletion and amortisation expense 3,820.00 7,660.00
(f) Other Expenses
1 Other expenses 14,370.00 28,770.00
Total other expenses 14,370.00 28,770.00
Total expenses 60,140.00 1,22,080.00
3 Total profit before exceptional items and tax 11,980.00 18,970.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 11,980.00 18,970.00
6 Tax expense
7 Current tax 2,530.00 4,200.00
8 Deferred tax 280.00 380.00
9 Total tax expenses 2,810.00 4,580.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,170.00 14,390.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,170.00 14,390.00
17 Other comprehensive income net of taxes (610.00) 550.00
18 Total Comprehensive Income for the period 8,560.00 14,940.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 81,480.00 81,480.00
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.56 0.88
Diluted earnings (loss) per share from continuing operations 0.56 0.88
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.56 0.88
Diluted earnings (loss) per share from continuing and discontinued operations 0.56 0.88
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on November 03, 2026 and approved by the Board of Directors of the Company at their meeting held on November 04, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘Syngene’) ii. Biocon Biologics Limited (‘BBL’) iii. Biocon Pharma Limited (‘BPL’) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil LTDA xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited (In the process of liquidation w.e.f 15 June 2026) xxi. Syngene Scientific Solutions Limited xxii. Biocon Biologics Ireland Limited (formerly known as Biosimilar Collaborations Ireland Limited) xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L.U xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece Single Members P.C. xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of these proceeds and cash balances: (a) The Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further, the Company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement, subsequently the Company exercised the right to conversion on May 07, 2026 and OCD were converted. (b) During the year ended March 31, 2026, the Company settled Commercial paper (‘CP’) for an aggregate value of Rs. 5,988 million; and (c) During the year ended March 31, 2026, the Company made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures that were issued to Kotak Special Situations Fund for an aggregate value to Rs. 15,390 million. (d) During the quarter ended March 31, 2026, the Company made early and full redemption of the 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures of face value Rs. 100,000 each for an aggregate value of Rs. 6,795 million, issued and allotted by the Company on May 19, 2023. 5. During the quarter ended March 31, 2026, the Company raised funds by way of allotment of 112,664,585 Equity Shares of face value Rs. 5 each at a price of Rs. 368.35 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 41,500 million, to acquire BBL equity shares from Mylan Inc., acquisition of Compulsorily Convertible Debentures (‘CCDs’) of BBL from Edelweiss and general corporate purposes. 6. On November 11, 2025, the Company entered into Debenture Purchase Agreement (‘DPA’) with ESOF III Investment Fund and EAAA India Alternatives Limited (collectively referred to as ‘Edelweiss’) for acquisition of 10,686,044 unlisted, secured, CCD of BBL for an aggregate value of Rs. 4,735 million against the gross obligation of Rs. 3,915 million. Resultant loss of Rs. 820 million is accounted under ‘other equity’ in line with accounting policy choice elected at time of initial recognition. The consideration towards the acquisition of these CCDs was paid during the quarter ended March 31, 2026 by the Company. The holder of CCD had the option to either redeem or convert the debentures into equity shares of BBL. Pursuant to acquisition of these CCD’s by the Company from Edelweiss, the Company has exercise the right to convert CCDs into equity shares on May 07, 2026 and CCD’s were converted. 7. Pursuant to the Board approval, the Company issued and allotted the Commercial Paper of Rs. 18,000 million on December 22, 2025 and of Rs. 2,000 million on January 02, 2026. The Company made early and full redemption of the Commercial Paper during the quarter ended March 31, 2026 from the funds raised through Qualified Institutional Placement on January 14, 2026. 8. During the year ended March 31, 2026, the Company entered into Share Swap Agreement (‘SSA’) with Tata Capital Growth Fund II and Activ Pine LLP for purchase of 33,957,771 equity shares in BBL against 23,863,769 equity shares of the Company on a preferential basis for consideration other than cash, aggregating up to Rs. 9,683 million against the gross obligation of Rs. 10,493 million. Resultant gain of Rs. 810 million is accounted under “other equity” in line with accounting policy choice at time of initial recognition. The preferential allotment of these shares were made on January 05, 2026 by the Company. 9. During the year ended March 31 2026, the Company acquired 112,860,496 equity shares of BBL from Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II and Activ Pine LLP and issued 79,312,534 equity shares of the Company on a preferential basis for consideration other than cash, aggregating up to Rs. 32,183 million subsequent to the approval by its Board of Directors in their meeting held on December 06, 2025 and shareholders meeting at the Extraordinary General Meeting (EGM) held on December 31, 2025. The Group recorded a loss on acquisition of equity shares in its subsidiary within other equity in the consolidated financial results. 10. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. 11. In accordance with Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Group’s performance based on an analysis of various performance indicators by business segments. The group has three reportable segments – Biosimilars, Generics and Services (earlier known as Contract Research, Development, and Manufacturing organization (CRDMO)). For segment reporting purposes, the Biosimilar and Generic businesses are presented as separate reportable segments within the Group’s Biopharmaceuticals business. The results of the Group, including related assets and liabilities pertaining to corporate activities undertaken by the Group, are included within “Unallocable” in the segment disclosures. Until March 31, 2026, the Group included corporate activities relating to cross charge of common utilities within “Generics” segment. During the quarter ended June 30, 2026, the CODM has started assessing the business performance of the Generics segment excluding the effect of such cross charges of common utilities and accordingly, the revenue, segment results and the corresponding assets and liabilities are included within “Unallocable” in the segment disclosure. The figures for the comparable periods have been restated to that effect. Until December 31, 2025, the Group included interest expenses relating to Optionally Convertible Debentures (OCDs) issued by BBL and held by the Company within ‘Biosimilars’ segment. During the quarter ended March 31, 2026, the CODM assessed the performance of ‘Biosimilars’ segment excluding the effect of inter-segment interest expenses and hence, the interest on such OCDs is included under ‘Unallocable expenditure/(income)’. The Group has restated segment information for the historical periods presented herein to conform to the current presentation. 12. During the quarter ended June 30, 2026, the Company acquired 1,15,36,956 equity shares of BBL, a material subsidiary of the Company, from selling shareholders through a share swap transaction. The acquisition was undertaken pursuant to the approval of the shareholders of the Company received through postal ballot on June 07, 2026, for a preferential issue of equity shares. Accordingly, on June 29, 2026, the Company allotted 87,86,362 equity shares of Rs. 5 each, fully paid-up, at an issue price of Rs. 376.41 per share on a preferential basis as consideration for the acquisition. Pursuant to this acquisition, BBL has become wholly owned subsidiary of the company w.e.f. June 29, 2026. The group recorded acquisition of equity shares in its subsidiary as an equity transaction. 13. On April 29, 2026, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 29, 2026, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2026. 14. On May 07, 2026, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/-. This was approved by the shareholders of Company in the Annual General Meeting dated August 06, 2026, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2026. 15. During the quarter ended June 30, 2026, the Board of Directors of Syngene International Limited approved the voluntary liquidation of its wholly owned subsidiary, Syngene Manufacturing Limited (SMSL), pursuant to a Board Resolution dated May 18, 2026. Subsequently, the shareholders approved the proposal for liquidation on June 15, 2026. As at September 30, 2026, the liquidation process is ongoing and is subject to the completion of the applicable statutory, regulatory and legal formalities. 16. Exceptional items: a. During the year ended March 31, 2026, quarter ended June 30, 2026, and September 30, 2026 termination benefits amounting to Rs. 303 million, Rs 135 million and Rs 67 million respectively were extended to employees in accordance with the approved policy. Considering the nature, significance and frequency of these benefits, these are disclosed as “Exceptional Items” in the consolidated financial results. b. On November 21, 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Group assessed and disclosed the incremental impact of these changes on gratuity and compensated absences, particularly relating to the definition of “wages” considering the salary structure existing on the date of notification of Labor Code. During the year ended March 31, 2026, the net expense recognised under “Exceptional Items” amounted to Rs. 223 million and Rs. 965 million in the standalone and consolidated financial results, respectively. The associated tax impact of Rs. 37 million and Rs. 112 million was included in the standalone and consolidated financial results respectively in the tax expense. c. On December 6, 2025, the Company entered into Share Swap and Share Purchase Agreement with Mylan Inc for purchase of 292,726,366 equity shares in BBL for consideration of Rs. 73,560 million (USD 815 million). Pursuant to above, the Company remeasured the derivative liability recorded earlier in relation to investment in BBL by Mylan Inc and recorded a gain of Rs. 1,842 million as an “exceptional item” in the consolidated financial results for the year ended March 31, 2026. The Company obtained shareholders’ approval at the EGM held on December 31, 2025, and accordingly (i) issued 91,967,019 equity shares on a preferential basis at a consideration other than cash aggregating to Rs. 37,318 million (USD 415 million) to acquire 149,056,984 equity shares of BBL on January 05, 2026; and (ii) paid cash consideration of Rs. 18,053 million (USD 200 million) and Rs. 18,189 million (USD 200 million) on January 05, 2026 and January 21, 2026 respectively to acquire 143,669,382 equity shares of BBL. The Group recorded a loss on acquisition of equity shares in its subsidiary within other equity in the consolidated financial results. d. In connection with various transactions referred to note 6 to note 9 above , the Company has incurred expenses towards advisory and legal consultancy services, premium paid on hedges taken for settlement of foreign currency payments, bridge financing cost in respect of commercial papers, additional finance cost towards settlement of certain lenders and settlement against outstanding receivables from Mylan Inc, aggregating Rs. 1,341 million and Rs. 2,102 million as an “exceptional item” in the standalone and consolidated financial results respectively for the year ended March 31, 2026. The associated tax impact of Rs. 222 million and Rs. 329 million was included in the tax expense for the year in the standalone and consolidated financial results. e. On December 6, 2025, the Company and BBL announced a strategic corporate action to fully integrate BBL as a wholly owned subsidiary into Biocon Limited. Pursuant to this, the Company and BBL accounted for expenses towards severance payments for certain employees, consultants fee for integration of businesses, employee stock option cost towards acceleration of vesting of ESOPs/ RSUs aggregating Rs 563 million and Rs 1,372 million in the standalone and consolidated financial results. Considering the nature, significance, and non recurring nature of these benefits, the related expenses were disclosed as exceptional items. The associated tax impact of Rs. 142 million and Rs. 387 million was included in the tax expense for the period in the standalone and consolidated financial results. f. During the year ended March 31, 2026, BBL has recorded an exceptional provision of Rs 762 million for inventories in respect of certain molecules in line with its assessment to liquidate these inventories. The provision recorded on these inventories, being high value and non-recurring, same is classified as an exceptional item. The associated tax impact of Rs. 107 million was included in the tax expense for the year. g. During the year ended March 31, 2026, the Group additionally invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management (‘IFQM’) a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2026, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million in the consolidated financial results and Rs. 25 million in the standalone financial results. h. During the quarter ended September 30, 2025, one of the subsidiaries of BBL reached a settlement on a litigation matter with one of its customers for a settlement amount of Rs. 119 million, which has been disclosed under “Exceptional Items”. The associated tax impact of Rs. 30 million included in the tax expense for the period. For the half year ended September 30, 2025, the total settlement amount aggregated to Rs. 291 million, with an associated tax impact of Rs. 73 million included in the tax expense for the period.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,21,040.00
Capital work-in-progress 56,330.00
Investment property 4,800.00
Goodwill 0.00
Other intangible assets 920.00
Intangible assets under development 1,790.00
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 25,32,290.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial assets 2,040.00
Total of other non-current financial assets 2,040.00
Total non-current financial assets 25,34,330.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current assets 6,110.00
2 ROU 3,910.00
3 Income-tax asset (net) 18,360.00
Total of other non-current assets 28,380.00
Total non-current assets 27,47,590.00
2 Current assets
Inventories 1,01,300.00
Current financial asset
Current investments 0.00
Trade receivables, current 1,12,980.00
Cash and cash equivalents 4,810.00
Bank balance other than cash and cash equivalents 4,860.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 6,880.00
Total current financial assets 1,29,530.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 8,640.00
Total of other current assets 8,640.00
Total current assets 2,39,470.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 29,87,060.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 81,480.00
Other equity 26,56,970.00
Total equity attributable to owners of parent 27,38,450.00
Non controlling interest
Total equity 27,38,450.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 60.00
2 Other financial liabilities 470.00
Total of other non-current financial liabilities 530.00
Total non-current financial liabilities 530.00
Provisions, non-current 6,220.00
Deferred tax liabilities (net) 1,260.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 4,880.00
Total of other non-current liabilities 4,880.00
Total non-current liabilities 12,890.00
Current liabilities
Current financial liabilities
Borrowings, current 1,32,490.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 5,500.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 65,170.00
Total Trade payable 70,670.00
Other current financial liabilities
1 Lease liabilities 190.00
2 Other financial liabilities 12,030.00
Total of other current financial liabilities 12,220.00
Total current financial liabilities 2,15,380.00
Other current liabilities 5,310.00
1 Other current liabilities 2,560.00
2 Provisions 2,750.00
Total of other current liabilities 5,310.00
Provisions, current 0.00
Current tax liabilities (Net) 15,030.00
Deferred government grants, Current
Total current liabilities 2,35,720.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,48,610.00
Total equity and liabilites 29,87,060.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes: 1. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on November 03, 2026 and approved by the Board of Directors of the Company at their meeting held on November 04, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘Syngene’) ii. Biocon Biologics Limited (‘BBL’) iii. Biocon Pharma Limited (‘BPL’) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil LTDA xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited (In the process of liquidation w.e.f 15 June 2026) xxi. Syngene Scientific Solutions Limited xxii. Biocon Biologics Ireland Limited (formerly known as Biosimilar Collaborations Ireland Limited) xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L.U xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece Single Members P.C. xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of these proceeds and cash balances: (a) The Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further, the Company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement, subsequently the Company exercised the right to conversion on May 07, 2026 and OCD were converted. (b) During the year ended March 31, 2026, the Company settled Commercial paper (‘CP’) for an aggregate value of Rs. 5,988 million; and (c) During the year ended March 31, 2026, the Company made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures that were issued to Kotak Special Situations Fund for an aggregate value to Rs. 15,390 million. (d) During the quarter ended March 31, 2026, the Company made early and full redemption of the 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures of face value Rs. 100,000 each for an aggregate value of Rs. 6,795 million, issued and allotted by the Company on May 19, 2023. 5. During the quarter ended March 31, 2026, the Company raised funds by way of allotment of 112,664,585 Equity Shares of face value Rs. 5 each at a price of Rs. 368.35 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 41,500 million, to acquire BBL equity shares from Mylan Inc., acquisition of Compulsorily Convertible Debentures (‘CCDs’) of BBL from Edelweiss and general corporate purposes. 6. On November 11, 2025, the Company entered into Debenture Purchase Agreement (‘DPA’) with ESOF III Investment Fund and EAAA India Alternatives Limited (collectively referred to as ‘Edelweiss’) for acquisition of 10,686,044 unlisted, secured, CCD of BBL for an aggregate value of Rs. 4,735 million against the gross obligation of Rs. 3,915 million. Resultant loss of Rs. 820 million is accounted under ‘other equity’ in line with accounting policy choice elected at time of initial recognition. The consideration towards the acquisition of these CCDs was paid during the quarter ended March 31, 2026 by the Company. The holder of CCD had the option to either redeem or convert the debentures into equity shares of BBL. Pursuant to acquisition of these CCD’s by the Company from Edelweiss, the Company has exercise the right to convert CCDs into equity shares on May 07, 2026 and CCD’s were converted. 7. Pursuant to the Board approval, the Company issued and allotted the Commercial Paper of Rs. 18,000 million on December 22, 2025 and of Rs. 2,000 million on January 02, 2026. The Company made early and full redemption of the Commercial Paper during the quarter ended March 31, 2026 from the funds raised through Qualified Institutional Placement on January 14, 2026. 8. During the year ended March 31, 2026, the Company entered into Share Swap Agreement (‘SSA’) with Tata Capital Growth Fund II and Activ Pine LLP for purchase of 33,957,771 equity shares in BBL against 23,863,769 equity shares of the Company on a preferential basis for consideration other than cash, aggregating up to Rs. 9,683 million against the gross obligation of Rs. 10,493 million. Resultant gain of Rs. 810 million is accounted under “other equity” in line with accounting policy choice at time of initial recognition. The preferential allotment of these shares were made on January 05, 2026 by the Company. 9. During the year ended March 31 2026, the Company acquired 112,860,496 equity shares of BBL from Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II and Activ Pine LLP and issued 79,312,534 equity shares of the Company on a preferential basis for consideration other than cash, aggregating up to Rs. 32,183 million subsequent to the approval by its Board of Directors in their meeting held on December 06, 2025 and shareholders meeting at the Extraordinary General Meeting (EGM) held on December 31, 2025. The Group recorded a loss on acquisition of equity shares in its subsidiary within other equity in the consolidated financial results. 10. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. 11. In accordance with Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Group’s performance based on an analysis of various performance indicators by business segments. The group has three reportable segments – Biosimilars, Generics and Services (earlier known as Contract Research, Development, and Manufacturing organization (CRDMO)). For segment reporting purposes, the Biosimilar and Generic businesses are presented as separate reportable segments within the Group’s Biopharmaceuticals business. The results of the Group, including related assets and liabilities pertaining to corporate activities undertaken by the Group, are included within “Unallocable” in the segment disclosures. Until March 31, 2026, the Group included corporate activities relating to cross charge of common utilities within “Generics” segment. During the quarter ended June 30, 2026, the CODM has started assessing the business performance of the Generics segment excluding the effect of such cross charges of common utilities and accordingly, the revenue, segment results and the corresponding assets and liabilities are included within “Unallocable” in the segment disclosure. The figures for the comparable periods have been restated to that effect. Until December 31, 2025, the Group included interest expenses relating to Optionally Convertible Debentures (OCDs) issued by BBL and held by the Company within ‘Biosimilars’ segment. During the quarter ended March 31, 2026, the CODM assessed the performance of ‘Biosimilars’ segment excluding the effect of inter-segment interest expenses and hence, the interest on such OCDs is included under ‘Unallocable expenditure/(income)’. The Group has restated segment information for the historical periods presented herein to conform to the current presentation. 12. During the quarter ended June 30, 2026, the Company acquired 1,15,36,956 equity shares of BBL, a material subsidiary of the Company, from selling shareholders through a share swap transaction. The acquisition was undertaken pursuant to the approval of the shareholders of the Company received through postal ballot on June 07, 2026, for a preferential issue of equity shares. Accordingly, on June 29, 2026, the Company allotted 87,86,362 equity shares of Rs. 5 each, fully paid-up, at an issue price of Rs. 376.41 per share on a preferential basis as consideration for the acquisition. Pursuant to this acquisition, BBL has become wholly owned subsidiary of the company w.e.f. June 29, 2026. The group recorded acquisition of equity shares in its subsidiary as an equity transaction. 13. On April 29, 2026, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 29, 2026, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2026. 14. On May 07, 2026, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/-. This was approved by the shareholders of Company in the Annual General Meeting dated August 06, 2026, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2026. 15. During the quarter ended June 30, 2026, the Board of Directors of Syngene International Limited approved the voluntary liquidation of its wholly owned subsidiary, Syngene Manufacturing Limited (SMSL), pursuant to a Board Resolution dated May 18, 2026. Subsequently, the shareholders approved the proposal for liquidation on June 15, 2026. As at September 30, 2026, the liquidation process is ongoing and is subject to the completion of the applicable statutory, regulatory and legal formalities. 16. Exceptional items: a. During the year ended March 31, 2026, quarter ended June 30, 2026, and September 30, 2026 termination benefits amounting to Rs. 303 million, Rs 135 million and Rs 67 million respectively were extended to employees in accordance with the approved policy. Considering the nature, significance and frequency of these benefits, these are disclosed as “Exceptional Items” in the consolidated financial results. b. On November 21, 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Group assessed and disclosed the incremental impact of these changes on gratuity and compensated absences, particularly relating to the definition of “wages” considering the salary structure existing on the date of notification of Labor Code. During the year ended March 31, 2026, the net expense recognised under “Exceptional Items” amounted to Rs. 223 million and Rs. 965 million in the standalone and consolidated financial results, respectively. The associated tax impact of Rs. 37 million and Rs. 112 million was included in the standalone and consolidated financial results respectively in the tax expense. c. On December 6, 2025, the Company entered into Share Swap and Share Purchase Agreement with Mylan Inc for purchase of 292,726,366 equity shares in BBL for consideration of Rs. 73,560 million (USD 815 million). Pursuant to above, the Company remeasured the derivative liability recorded earlier in relation to investment in BBL by Mylan Inc and recorded a gain of Rs. 1,842 million as an “exceptional item” in the consolidated financial results for the year ended March 31, 2026. The Company obtained shareholders’ approval at the EGM held on December 31, 2025, and accordingly (i) issued 91,967,019 equity shares on a preferential basis at a consideration other than cash aggregating to Rs. 37,318 million (USD 415 million) to acquire 149,056,984 equity shares of BBL on January 05, 2026; and (ii) paid cash consideration of Rs. 18,053 million (USD 200 million) and Rs. 18,189 million (USD 200 million) on January 05, 2026 and January 21, 2026 respectively to acquire 143,669,382 equity shares of BBL. The Group recorded a loss on acquisition of equity shares in its subsidiary within other equity in the consolidated financial results. d. In connection with various transactions referred to note 6 to note 9 above , the Company has incurred expenses towards advisory and legal consultancy services, premium paid on hedges taken for settlement of foreign currency payments, bridge financing cost in respect of commercial papers, additional finance cost towards settlement of certain lenders and settlement against outstanding receivables from Mylan Inc, aggregating Rs. 1,341 million and Rs. 2,102 million as an “exceptional item” in the standalone and consolidated financial results respectively for the year ended March 31, 2026. The associated tax impact of Rs. 222 million and Rs. 329 million was included in the tax expense for the year in the standalone and consolidated financial results. e. On December 6, 2025, the Company and BBL announced a strategic corporate action to fully integrate BBL as a wholly owned subsidiary into Biocon Limited. Pursuant to this, the Company and BBL accounted for expenses towards severance payments for certain employees, consultants fee for integration of businesses, employee stock option cost towards acceleration of vesting of ESOPs/ RSUs aggregating Rs 563 million and Rs 1,372 million in the standalone and consolidated financial results. Considering the nature, significance, and non recurring nature of these benefits, the related expenses were disclosed as exceptional items. The associated tax impact of Rs. 142 million and Rs. 387 million was included in the tax expense for the period in the standalone and consolidated financial results. f. During the year ended March 31, 2026, BBL has recorded an exceptional provision of Rs 762 million for inventories in respect of certain molecules in line with its assessment to liquidate these inventories. The provision recorded on these inventories, being high value and non-recurring, same is classified as an exceptional item. The associated tax impact of Rs. 107 million was included in the tax expense for the year. g. During the year ended March 31, 2026, the Group additionally invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management (‘IFQM’) a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2026, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million in the consolidated financial results and Rs. 25 million in the standalone financial results. h. During the quarter ended September 30, 2025, one of the subsidiaries of BBL reached a settlement on a litigation matter with one of its customers for a settlement amount of Rs. 119 million, which has been disclosed under “Exceptional Items”. The associated tax impact of Rs. 30 million included in the tax expense for the period. For the half year ended September 30, 2025, the total settlement amount aggregated to Rs. 291 million, with an associated tax impact of Rs. 73 million included in the tax expense for the period.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (1,310.00) (330.00)
Total Amount of items that will not be reclassified to profit and loss (1,310.00) (330.00)
2 Income tax relating to items that will not be reclassified to profit or loss (200.00) (80.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 670.00 1,070.00
Total Amount of items that will be reclassified to profit and loss 670.00 1,070.00
4 Income tax relating to items that will be reclassified to profit or loss 170.00 270.00
5 Total Other comprehensive income (610.00) 550.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 18,970.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 3,920.00
Adjustments for decrease (increase) in inventories (13,790.00)
Adjustments for decrease (increase) in trade receivables, current (14,180.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 10.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 11,930.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 7,660.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 520.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 580.00
Adjustments for dividend income 2,640.00
Adjustments for interest income 30.00
Adjustments for share-based payments 290.00
Adjustments for fair value losses (gains) (12,510.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (50.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 100.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (18,190.00)
Net cash flows from (used in) operations 780.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,700.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (920.00)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 5,720.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 550.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 7,970.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 100.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 2,640.00
Interest received 30.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 12,420.00
Net cash flows from (used in) investing activities 750.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 40.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 25,400.00
Repayments of borrowings 8,350.00
Payments of lease liabilities 70.00
Dividends paid 8,150.00
Interest paid 3,200.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (9,960.00)
Net cash flows from (used in) financing activities (4,290.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,460.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 130.00
Net increase (decrease) in cash and cash equivalents (4,330.00)
Cash and cash equivalents cash flow statement at beginning of period 9,140.00
Cash and cash equivalents cash flow statement at end of period 4,810.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Biocon Limited Syngene International Limited Subsidiary Any other transaction Other expenses recovery 4,000.00 No remarks by the Audit Committee 1,330.00 530.00 1,271.60
2 Syngene International Limited Professor Catherine Rosenberg Non-Executive Director Any other transaction Sitting fees & Commission 100.00 No remarks by the Audit Committee 23.90 0.00 0.00
3 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 0.00 No remarks by the Audit Committee 1,110.00 0.00 0.00
4 Syngene International Limited Syngene USA Inc Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 0.00 No remarks by the Audit Committee 70.00 518.30 143.60
5 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Expenses reimbursement receivable 210.00 No remarks by the Audit Committee 210.00 0.00 0.00
6 Syngene International Limited Biocon Academy Fellow subsidiary Any other transaction CSR 500.00 No remarks by the Audit Committee 155.50 40.00 0.00
7 Syngene International Limited Biocon Foundation Trust in which a director is a trustee Any other transaction CSR 1,200.00 No remarks by the Audit Committee 263.50 40.00 40.00
8 Syngene International Limited Jeeves Enterprise in which a member of the Promoter Group is a Partner Any other transaction Laundry service 100.00 No remarks by the Audit Committee 20.00 0.00 (10.00)
9 Biocon Biologics Limited Biocon SDN. BHD. Subsidiary Any other transaction Guarantee given 0.00 No remarks by the Audit Committee 0.00 (9,348.00) (9,595.00)
10 Biocon Biologics Limited Biocon Biologics Global P Subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BBIRL, BBIL and BBUK PLC 0.00 No remarks by the Audit Committee 0.00 (7,47,840.00) (7,67,581.20)
11 Biocon Biologics Limited Biocon Biologics UK PLC Subsidiary Any other transaction Guarantee given towards Debt obtained by BBUK PLC, jointly/severally by BBL, BSDN, BBIRL, BBIL and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,99,136.00) (3,07,032.50)
12 Biocon Biologics Intl Ltd Biocon Biologics Global P Subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BBIRL, BBIL and BBUK PLC 0.00 No remarks by the Audit Committee 0.00 (8,22,624.00) (8,44,339.30)
13 Biocon Biologics Intl Ltd Biocon Biologics UK PLC Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BBUK PLC, jointly/severally by BBL, BSDN, BBIRL, BBIL and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,99,136.00) (3,07,032.50)
14 Biocon SDN. BHD. Biocon Biologics Global P Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BBIRL, BBIL and BBUK PLC 0.00 No remarks by the Audit Committee 0.00 (8,22,624.00) (8,44,339.30)
15 Biocon SDN. BHD. Biocon Biologics UK PLC Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BBUK PLC, jointly/severally by BBL, BSDN, BBIRL, BBIL and BBGP 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
16 Biocon Biologics UK PLC Biocon Biologics Global P Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BBIRL, BBIL and BBUK PLC 0.00 No remarks by the Audit Committee 0.00 (8,22,624.00) (8,44,339.30)
17 Biocon Biologics Ire Ltd Biocon Biologics Global P Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BBIRL, BBIL and BBUK PLC 0.00 No remarks by the Audit Committee 0.00 (8,22,624.00) (8,44,339.30)
18 Biocon Biologics Ire Ltd Biocon Biologics UK PLC Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BBUK PLC, jointly/severally by BBL, BSDN, BBIRL, BBIL and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,99,136.00) (3,07,032.50)
19 Biocon Biologics Global P Biocon Biologics UK PLC Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BBUK PLC, jointly/severally by BBL, BSDN, BBIRL, BBIL and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,99,136.00) (3,07,032.50)
20 Biocon Limited Biocon Pharma Limited Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 40.20 0.00 0.00
21 Biocon Limited Biocon Pharma Inc Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 103.90 0.00 0.00
22 Biocon Limited Biocon Pharma Inc Subsidiary Any other transaction Charges for issue of corporate guarantee 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
23 Biocon Limited Biocon FZ LLC Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 11.50 0.00 0.00
24 Biocon Limited Biocon Academy Subsidiary Any other transaction CSR 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
25 Biocon Limited Biocon Biosphere Limited Subsidiary Any other transaction Charges for issue of corporate guarantee 0.00 No remarks by the Audit Committee 281.90 0.00 0.00
26 Biocon Limited Biocon Biosphere Limited Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
27 Biocon Limited Biocon Pharma UK Ltd Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
28 Biocon Limited Biocon Pharma Malta I Ltd Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 57.70 0.00 0.00
29 Biocon Limited Biocon Generics Inc Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 11.50 0.00 0.00
30 Biocon Limited Biocon Generics Inc Subsidiary Any other transaction Charges for issue of corporate guarantee 0.00 No remarks by the Audit Committee 48.50 0.00 0.00
31 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
32 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Conversion of OCD into Investments 0.00 No remarks by the Audit Committee 1,63,430.00 0.00 0.00
33 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Conversion of CCD into Investments 0.00 No remarks by the Audit Committee 30,000.00 0.00 0.00
34 Biocon Limited Biocon SDN. BHD. Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
35 Biocon Limited Biocon Biologics Intl Ltd Subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
36 Biocon Limited Biocon Foundation Trust in which KMP are the Board of Trustees Any other transaction CSR 420.00 No remarks by the Audit Committee 53.50 0.00 0.00
37 Biocon Limited Biocon Pharma Limited Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 26.00 26.00
38 Biocon Limited Biocon Pharma Limited Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 21,829.00 36,091.70
39 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (108.00) (909.70)
40 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 9,478.00 6,176.00
41 Biocon Limited Biocon Biosphere Limited Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (11,700.00) (8,071.90)
42 Biocon Limited Biocon Biosphere Limited Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 7,390.00 8,756.20
43 Biocon Limited Biocon FZ LLC Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (670.00) (781.80)
44 Biocon Limited Biocon FZ LLC Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 3.80 49.60
45 Biocon Limited Biocon Biologics Intl Ltd Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (72.00) (74.20)
46 Biocon Limited Biocon Biologics Intl Ltd Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 106.00 109.30
47 Biocon Limited Biocon Pharma Inc Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (2,727.00) (3,129.10)
48 Biocon Limited Biocon Pharma Inc Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 3,322.00 3,898.60
49 Biocon Limited Biocon Pharma Malta I Ltd Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 57.70
50 Biocon Limited Biocon Generics Inc Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (1.40) (14.80)
51 Biocon Limited Biocon Generics Inc Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 6,584.00 4,690.60
52 Biocon Limited Biocon SDN. BHD. Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 3.20 5.10
53 Biocon Limited Biocon SDN. BHD. Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 173.00 175.30
54 Biocon Limited Biocon Biologics Ire Ltd Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 9.30 1,049.50
55 Biocon Limited Biocon Biologics UK PLC Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 1,753.60
56 Biocon Limited Biocon Academy Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 219.00 219.60
57 Biocon Limited Biocon Academy Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 39.90 39.90
58 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (3,509.00) (6,860.00)
59 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 982.00 984.20
60 Biocon Pharma Limited Biocon Biosphere Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 3.00 (3.10)
61 Biocon Pharma Limited Biocon Biosphere Limited Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 1,126.30 1,187.40
62 Biocon Pharma Limited Biocon FZ LLC Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (21.00) (22.10)
63 Biocon Pharma Limited Biocon FZ LLC Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 0.30
64 Biocon Pharma Limited Biocon Pharma Inc Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 8,942.00 (9,150.50)
65 Biocon Pharma Limited Biocon Pharma Inc Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 37,017.00 20,449.20
66 Biocon Pharma Limited Biocon Pharma UK Ltd Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (1,476.00) (1,374.30)
67 Biocon Pharma Limited Biocon Pharma UK Ltd Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 1,946.00 482.20
68 Biocon Pharma Limited Biocon Pharma Ireland Ltd Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.50 0.50
69 Biocon Pharma Limited Biocon Pharma Malta Ltd Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 16.50 16.50
70 Biocon Pharma Limited Biocon Pharma Malta I Ltd Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (576.00) (1,819.10)
71 Biocon Pharma Limited Biocon Pharma Malta I Ltd Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 1,648.00 7,037.00
72 Biocon Pharma Limited Biocon Generics Inc Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (337.00) (346.00)
73 Biocon Pharma Limited Biocon Generics Inc Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 444.00 793.90
74 Biocon Pharma Limited Biocon Biologics Ire Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 268.00 409.50
75 Biocon Pharma Limited Biocon Biologics UK PLC Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
76 Biocon Biosphere Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (518.90) (518.90)
77 Biocon Biosphere Limited Biocon Biologics UK PLC Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.90 0.90
78 Biocon SA Biocon Pharma Inc Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 622.00 0.00 976.10
79 Biocon SA Biocon Pharma Malta I Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 15.00 0.00 28.20
80 Biocon FZ LLC Biocon SDN. BHD. Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (2.80) (243.90)
81 Biocon Biologics FZ-LLC Biocon FZ LLC Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (4.80) (4.80)
82 Biocon Pharma Inc Biocon SA Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (622.80) (976.70)
83 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 8,846.00 9,716.80
84 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 370.70 733.00
85 Biocon Pharma UK Ltd Biocon Biologics Intl Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 5.50 5.70
86 Biocon Pharma UK Ltd Biocon Pharma Malta Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 6.40 6.60
87 Biocon Pharma Malta I Ltd Biocon Pharma Ireland Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 (25.30) (25.30)
88 Biocon Pharma Malta I Ltd Biocon Pharma Malta Ltd Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 (36.00) (35.60)
89 Biocon Pharma Malta I Ltd Biocon Pharma Malta Ltd Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 12.20 12.20
90 Biocon Pharma Malta I Ltd Biocon Biologics Germany Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 1,170.60
91 Biocon Pharma Limited Biocon Foundation Trust in which KMP are the Board of Trustees Any other transaction CSR 150.00 No remarks by the Audit Committee 10.00 0.00 0.00
92 Biocon Limited Biocon Biosphere Limited Subsidiary Interest received 0.00 No remarks by the Audit Committee 64.70 0.00 0.00
93 Biocon Limited Biocon Biologics Limited Subsidiary Interest received 0.00 No remarks by the Audit Committee 12,458.00 0.00 0.00
94 Biocon SA Biocon Pharma Inc Fellow subsidiary Interest received 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
95 Biocon SA Biocon Pharma Inc Fellow subsidiary Interest received 0.00 No remarks by the Audit Committee 105.90 0.00 0.00
96 Biocon SA Biocon Pharma Malta I Ltd Fellow subsidiary Interest received 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
97 Biocon SA Biocon Pharma Malta I Ltd Fellow subsidiary Interest received 0.00 No remarks by the Audit Committee 3.70 0.00 0.00
98 Biocon Pharma Limited Biocon Pharma Inc Subsidiary Investment 0.00 No remarks by the Audit Committee 23,940.00 0.00 0.00
99 Biocon Pharma Limited Biocon Generics Inc Subsidiary Investment 0.00 No remarks by the Audit Committee 9,510.00 0.00 0.00
100 Biocon Limited Biocon Biosphere Limited Subsidiary Loan 0.00 No remarks by the Audit Committee 3,970.00 0.00 0.00
101 Biocon Limited Biocon Pharma Limited Subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 1,08,618.10 1,08,618.10
102 Biocon Pharma Limited Biocon Generics Inc Subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 267.00 24.50
103 Biocon SA Biocon Pharma Inc Fellow subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 (13,778.00) 13,912.80
104 Biocon SA Biocon Pharma Malta I Ltd Fellow subsidiary Loan 0.00 No remarks by the Audit Committee 464.70 0.00 468.70
105 Biocon Pharma Malta I Ltd Biocon Pharma Ireland Ltd Fellow subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 25.50 25.50
106 Syngene International Limited Biocon Pharma Inc Fellow subsidiary Purchase of fixed assets 60.00 No remarks by the Audit Committee 40.00 0.00 0.00
107 Biocon Limited Biocon Biologics Limited Subsidiary Purchase of fixed assets 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
108 Biocon Limited Biocon Biologics Limited Subsidiary Purchase of fixed assets 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
109 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 30.00 0.00 0.00
110 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 1,650.00 No remarks by the Audit Committee 100.00 (56.60) (152.80)
111 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 2,440.00 (712.40) (636.90)
112 Syngene International Limited Syngene USA Inc Wholly Owned Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 3,780.00 (443.10) (443.10)
113 Syngene International Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 200.00 No remarks by the Audit Committee 70.00 (94.90) (110.00)
114 Syngene International Limited SOTC Travel Limited Enterprise in which a Director of the Company is a member of the Board of Directors of Holding Company Purchase of goods or services 2,500.00 No remarks by the Audit Committee 70.00 (120.00) 0.00
115 Biocon Biologics Limited Biocon SDN. BHD. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 5,498.90 0.00 0.00
116 Biocon Biologics Limited Biocon Biologics Ire Ltd Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 3,995.60 0.00 0.00
117 Biocon Biologics Limited Biocon Biologics UK PLC Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
118 Biocon Biologics Limited Jeeves Enterprise in which a member of the Promoter Group is a Partner Purchase of goods or services 500.00 No remarks by the Audit Committee 133.40 (9.10) (4.80)
119 Biocon Biologics Limited Biocon Academy Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 200.00 137.70 2,027.20
120 Biocon Biologics Limited Biocon Foundation Trust in which KMP are the Board of Trustees Purchase of goods or services 1,800.00 No remarks by the Audit Committee 200.00 0.00 0.00
121 Biocon Biologics Limited Biocon Biologics Inc. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 2.60 0.00 0.00
122 Biocon Biologics Intl Ltd Biocon Biologics Inc. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (0.30) (0.30)
123 Biocon Biologics Intl Ltd Biocon Biologics Brasil Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 1,250.00 1,545.60
124 Biocon Biologics Intl Ltd Biocon Biologics FZ-LLC Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 169.10 174.40
125 Biocon Biologics Intl Ltd Biocon Biologics Canada Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.20 0.20
126 Biocon Biologics Intl Ltd Biocon Biologics Thailand Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 20.30 20.90
127 Biocon Biologics Intl Ltd Biocon Biologics Morocco Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 868.70 966.00
128 Biocon Biologics Intl Ltd Biocon Biologics S Africa Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 156.60 160.70
129 Biocon Biologics Intl Ltd Biocon Biologics PH Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 286.80 294.40
130 Biocon Biologics Intl Ltd Biocon SDN. BHD. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (4.60) (4.70)
131 Biocon Biologics Intl Ltd Biocon Healthcare Sdn.Bhd Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 5.50 6.10
132 Biocon Biologics Intl Ltd Biocon Biologics Ire Ltd Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
133 Biocon Biologics Intl Ltd Biocon Biologics UK PLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
134 Biocon Biologics Intl Ltd Biocon Biologics Belgium Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.90 1.00
135 Biocon Biologics Intl Ltd Biocon Biologics Italy Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 17.70 18.10
136 Biocon SDN. BHD. Biocon Biologics FZ-LLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 200.30 (441.00) (654.20)
137 Biocon SDN. BHD. Biocon Biologics Inc. Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
138 Biocon SDN. BHD. Biocon Biologics Thailand Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 2.80 2.80
139 Biocon SDN. BHD. Biocon Healthcare Sdn.Bhd Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 24.10 24.50
140 Biocon SDN. BHD. Biocon Biologics Ire Ltd Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
141 Biocon SDN. BHD. Biocon Biologics UK PLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
142 Biocon Biologics UK PLC Biocon Biologics Inc. Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
143 Biocon Biologics UK PLC Biocon Biologics Brasil Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 3,949.20 (1,458.10) (2,561.20)
144 Biocon Biologics UK PLC Biocon Biologics FZ-LLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 459.20 (1,219.00) (1,420.60)
145 Biocon Biologics UK PLC Biocon Biologics Thailand Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 531.40 (715.00) (760.70)
146 Biocon Biologics UK PLC Biocon Biologics Morocco Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 2,192.20 (821.40) (608.40)
147 Biocon Biologics UK PLC Biocon Biologics S Africa Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 261.80 (237.20) (362.20)
148 Biocon Biologics UK PLC Biocon Biologics PH Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 679.90 (739.00) (597.50)
149 Biocon Biologics UK PLC Biocon Biologics Germany Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 943.50 7,273.10 570.60
150 Biocon Biologics UK PLC Biocon Biologics Finland Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 34.30 (251.90) (288.70)
151 Biocon Biologics UK PLC Biocon Biologics Belgium Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 187.60 25.90 217.50
152 Biocon Biologics UK PLC Biocon Biologics Greece Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 1,200.60 1,261.60
153 Biocon Biologics UK PLC Biocon Biologics Swiss Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 467.40 (1,069.30) (1,522.30)
154 Biocon Biologics UK PLC Biocon Biologics Italy Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 667.10 (226.70) (869.30)
155 Biocon Biologics UK PLC Biocon Biologics Croatia Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 457.70 (171.40) (494.80)
156 Biocon Biologics UK PLC Biocon Biologics Global P Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 170.10 17,873.60 20,494.50
157 Biocon Biologics Ire Ltd Biocon Biologics Inc. Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
158 Biocon Biologics Ire Ltd Biocon Biologics Brasil Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
159 Biocon Biologics Ire Ltd Biocon Biologics FZ-LLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 7.80 4.20 (3.50)
160 Biocon Biologics Ire Ltd Biocon Biologics Canada Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
161 Biocon Biologics Ire Ltd Biocon Biologics Thailand Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 115.00 (52.90) (170.80)
162 Biocon Biologics Ire Ltd Biocon Biologics Morocco Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 89.40 (1,621.00) (319.60)
163 Biocon Biologics Ire Ltd Biocon Biologics S Africa Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 10.20 0.00 0.00
164 Biocon Biologics Ire Ltd Biocon Biologics PH Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 63.40 0.00 0.00
165 Biocon Biologics Ire Ltd Biocon Biologics Germany Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
166 Biocon Biologics Ire Ltd Biocon Biologics France Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
167 Biocon Biologics Ire Ltd Biocon Biologics Spain Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
168 Biocon Biologics Ire Ltd Biocon Biologics Finland Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 10.00 (215.80) 22.60
169 Biocon Biologics Ire Ltd Biocon Biologics Belgium Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 1,436.10 (614.20) (222.00)
170 Biocon Biologics Ire Ltd Biocon Biologics Greece Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (9,322.10) (6,311.70)
171 Biocon Biologics Ire Ltd Biocon Biologics Italy Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (2.80) 117.20
172 Biocon Biologics Ire Ltd Biocon Biologics Croatia Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 462.70 (2.90) 171.00
173 Biocon Biologics Ire Ltd Biocon Biologics UK PLC Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 37,846.90 0.00 0.00
174 Biocon Biologics Inc. Biocon Biologics Global P Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 2,718.80 2,790.60
175 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 2.00 0.00 0.00
176 Biocon Limited Biocon Pharma Inc Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
177 Biocon Limited Biocon FZ LLC Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 90.00 0.00 0.00
178 Biocon Limited Biocon Biologics Limited Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
179 Biocon Limited Biocon Biologics Limited Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
180 Biocon Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 220.00 No remarks by the Audit Committee 0.00 0.00 0.00
181 Biocon Limited Jeeves Enterprise in which a member of the Promoter Group is a Partner Purchase of goods or services 460.00 No remarks by the Audit Committee 85.30 0.00 0.00
182 Biocon Limited Mazumdar Shaw Medical Foundation Trust in which KMP are the Board of Trustees Purchase of goods or services 22.00 No remarks by the Audit Committee 0.00 0.00 0.00
183 Biocon FZ LLC Biocon SDN. BHD. Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee (93.20) 0.00 0.00
184 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee (5,160.80) 0.00 0.00
185 Biocon Pharma Malta I Ltd Biocon Biologics Ire Ltd Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
186 Biocon Pharma Malta I Ltd Biocon Biologics Germany Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
187 Biocon Limited Jeeves Promoter Group Purchase of goods or services 460.00 No remarks by the Audit Committee 85.30 37.20 20.70
188 Syngene International Limited Kiran Mazumdar Shaw Executive Chairperson Remuneration 600.00 No remarks by the Audit Committee 195.10 0.00 0.00
189 Biocon Limited Kiran Mazumdar Shaw Executive Chairperson Remuneration 0.00 No remarks by the Audit Committee 774.70 0.00 0.00
190 Biocon Limited Syngene International Limited Subsidiary Sale of fixed assets 90.00 No remarks by the Audit Committee 60.00 0.00 0.00
191 Biocon Limited Biocon Pharma Limited Subsidiary Sale of fixed assets 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
192 Biocon Limited Biocon Biologics Limited Subsidiary Sale of fixed assets 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
193 Biocon Limited Syngene International Limited Subsidiary Sale of goods or services 2,500.00 No remarks by the Audit Committee 730.00 0.00 0.00
194 Biocon Limited Syngene International Limited Subsidiary Sale of goods or services 1,400.00 No remarks by the Audit Committee 500.00 0.00 0.00
195 Syngene International Limited Abergy INC Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 2,000.00 No remarks by the Audit Committee 409.30 478.70 268.80
196 Syngene International Limited Bicara Therapeutics Inc. Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 15,000.00 No remarks by the Audit Committee 2,664.80 1,336.40 1,005.80
197 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 1,000.00 No remarks by the Audit Committee 20.00 313.20 1,689.00
198 Syngene International Limited Biocon Biologics Intl Ltd Fellow subsidiary Sale of goods or services 950.00 No remarks by the Audit Committee 10.00 100.70 20.00
199 Syngene International Limited Biocon Pharma Limited Fellow subsidiary Sale of goods or services 200.00 No remarks by the Audit Committee 60.00 59.20 3.50
200 Syngene International Limited Biocon Biologics UK PLC Fellow subsidiary Sale of goods or services 1,100.00 No remarks by the Audit Committee 229.70 10.00 100.20
201 Syngene International Limited Immuneel Therapeutics Private Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 800.00 No remarks by the Audit Committee 270.00 71.80 252.40
202 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 170.30 320.00 365.80
203 Syngene International Limited Therapoma Inc Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 100.00 No remarks by the Audit Committee 90.00 10.00 64.90
204 Syngene International Limited Third Arc Bio Enterprise in which a Director of the Company has significant influence Sale of goods or services 6,000.00 No remarks by the Audit Committee 2,486.30 1,244.10 281.10
205 Syngene International Limited Syngene USA Inc Wholly Owned Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 175.20 0.00 0.00
206 Syngene International Limited Puretech Health, USA Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 950.00 No remarks by the Audit Committee 100.00 (200.30) (320.00)
207 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 400.00 No remarks by the Audit Committee 140.00 0.00 0.00
208 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 1,400.00 No remarks by the Audit Committee 370.00 0.00 0.00
209 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 1,500.00 No remarks by the Audit Committee 1,285.50 0.00 0.00
210 Biocon Biologics Limited Biocon SDN. BHD. Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 2,220.60 (128.30) (3,857.50)
211 Biocon Biologics Limited Biocon Biologics Intl Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 34,528.80 24,608.50
212 Biocon Biologics Limited Biocon Biologics Ire Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 46,021.60 20,436.80 33,939.80
213 Biocon Biologics Limited Biocon Biologics Global P Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 5.20 2,213.80 2,415.90
214 Biocon Biologics Limited Biocon Biologics UK PLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,08,843.30 83,058.50 28,240.90
215 Biocon Biologics Limited Biocon Biologics Germany Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.20 0.00
216 Biocon Biologics Limited Biocon Biologics Swiss Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
217 Biocon Biologics Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 1,100.00 No remarks by the Audit Committee 0.00 0.00 14.60
218 Biocon Biologics Limited Biocon Academy Fellow subsidiary Sale of goods or services 1,000.00 No remarks by the Audit Committee 69.70 0.00 0.00
219 Biocon Biologics Limited Biocon Biologics Inc. Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 (353.90) (408.10)
220 Biocon Biologics Limited Biocon Biologics Canada Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 10.70 25.00 27.40
221 Biocon Biologics Limited Biocon Biologics PH Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 4.60 6.00
222 Biocon Biologics Intl Ltd Biocon Biologics Inc. Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 (0.30) 0.00
223 Biocon Biologics Intl Ltd Biocon Biologics Brasil Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
224 Biocon Biologics Intl Ltd Biocon Biologics FZ-LLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
225 Biocon Biologics Intl Ltd Biocon Biologics Global P Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 831.40 853.30
226 Biocon Biologics Intl Ltd Biocon Biologics Ire Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 7,960.10 (5,262.60)
227 Biocon Biologics Intl Ltd Biocon Biologics UK PLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 12,705.30 59,573.10 64,258.20
228 Biocon SDN. BHD. Biocon Biologics FZ-LLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
229 Biocon SDN. BHD. Biocon Biologics Inc. Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
230 Biocon SDN. BHD. Biocon Biologics Brasil Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
231 Biocon SDN. BHD. Biocon Biologics Ire Ltd Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 9,377.90 (269.80) 4,682.10
232 Biocon SDN. BHD. Biocon Biologics Global P Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 18.70 (14,108.90) (14,462.90)
233 Biocon SDN. BHD. Biocon Biologics UK PLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 76,579.10 (54,601.30) (50,862.00)
234 Biocon Biologics UK PLC Biocon Biologics Canada Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 4,304.00 (24,194.30) (28,250.60)
235 Biocon Biologics UK PLC Biocon Biologics Inc. Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,55,328.30 (10,091.90) (23,362.30)
236 Biocon Biologics UK PLC Biocon Biologics Brasil Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
237 Biocon Biologics UK PLC Biocon Biologics FZ-LLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
238 Biocon Biologics UK PLC Biocon Biologics Thailand Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
239 Biocon Biologics UK PLC Biocon Biologics Morocco Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
240 Biocon Biologics UK PLC Biocon Biologics S Africa Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
241 Biocon Biologics UK PLC Biocon Biologics PH Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 134.30 0.00 0.00
242 Biocon Biologics UK PLC Biocon Biologics Germany Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 6,027.20 0.00 0.00
243 Biocon Biologics UK PLC Biocon Biologics France Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 2,347.90 12,486.70 14,839.30
244 Biocon Biologics UK PLC Biocon Biologics Spain Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 12.20 (780.80) (807.20)
245 Biocon Biologics UK PLC Biocon Biologics Finland Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
246 Biocon Biologics UK PLC Biocon Biologics Belgium Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
247 Biocon Biologics UK PLC Biocon Biologics Greece Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 505.50 0.00 0.00
248 Biocon Biologics UK PLC Biocon Biologics Swiss Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
249 Biocon Biologics UK PLC Biocon Biologics Italy Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
250 Biocon Biologics UK PLC Biocon Biologics Croatia Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
251 Biocon Biologics UK PLC Biocon Biologics Global P Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 29.50 0.00 0.00
252 Biocon Biologics Ire Ltd Biocon Biologics Inc. Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 32,680.70 (14,983.90) (16,028.90)
253 Biocon Biologics Ire Ltd Biocon Biologics Brasil Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 21.10 21.70
254 Biocon Biologics Ire Ltd Biocon Biologics FZ-LLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 4.20 0.00
255 Biocon Biologics Ire Ltd Biocon Biologics Canada Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 14,358.60 (1,807.40) 5,426.20
256 Biocon Biologics Ire Ltd Biocon Biologics Thailand Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
257 Biocon Biologics Ire Ltd Biocon Biologics Morocco Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
258 Biocon Biologics Ire Ltd Biocon Biologics S Africa Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 200.00
259 Biocon Biologics Ire Ltd Biocon Biologics PH Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 42.30 11.80 (8.70)
260 Biocon Biologics Ire Ltd Biocon Biologics Germany Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 37,638.70 46,955.20 35,736.70
261 Biocon Biologics Ire Ltd Biocon Biologics France Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 18,380.00 (2,800.10) (10,166.80)
262 Biocon Biologics Ire Ltd Biocon Biologics Spain Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 6,413.30 7,675.10 8,820.00
263 Biocon Biologics Ire Ltd Biocon Biologics Finland Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 38.60 0.00 0.00
264 Biocon Biologics Ire Ltd Biocon Biologics Belgium Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
265 Biocon Biologics Ire Ltd Biocon Biologics Greece Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 5,850.00 0.00 0.00
266 Biocon Biologics Ire Ltd Biocon Biologics Swiss Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 370.20 1,762.10 180.50
267 Biocon Biologics Ire Ltd Biocon Biologics Italy Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 (2.80) 0.00
268 Biocon Biologics Ire Ltd Biocon Biologics Croatia Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
269 Biocon Biologics Ire Ltd Biocon Biologics Global P Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 831.40 853.30
270 Biocon Biologics Ire Ltd Biocon Biologics UK PLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,077.10 (1,13,471.40) (1,04,501.30)
271 Biocon Biologics Inc. Biocon Biologics Canada Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 28.60
272 Biocon Biologics Inc. Biocon Biologics Global P Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
273 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 3,350.30 0.00 (5,175.80)
274 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 20,512.10 0.00 0.00
275 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 90.30 0.00 0.00
276 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 731.10 0.00 0.00
277 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
278 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 913.70 0.00 0.00
279 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
280 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 55.40 0.00 0.00
281 Biocon Limited Biocon Pharma Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
282 Biocon Limited Biocon Pharma Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 392.70 0.00 0.00
283 Biocon Limited Biocon Pharma Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 669.90 0.00 0.00
284 Biocon Limited Biocon FZ LLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
285 Biocon Limited Biocon FZ LLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
286 Biocon Limited Biocon Academy Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
287 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,761.20 0.00 0.00
288 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 706.90 0.00 0.00
289 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
290 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,487.00 0.00 0.00
291 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 544.80 0.00 0.00
292 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 64.50 0.00 0.00
293 Biocon Limited Biocon Biosphere Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 64.50 0.00 0.00
294 Biocon Limited Biocon Pharma UK Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
295 Biocon Limited Biocon Pharma Malta I Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
296 Biocon Limited Biocon Pharma Ireland Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
297 Biocon Limited Biocon Generics Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 3,719.00 0.00 0.00
298 Biocon Limited Biocon Generics Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
299 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 9,095.50 0.00 0.00
300 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,568.20 0.00 0.00
301 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 656.40 0.00 0.00
302 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 471.00 0.00 0.00
303 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 2,320.90 0.00 0.00
304 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
305 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
306 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 14.50 0.00 0.00
307 Biocon Limited Biocon SDN. BHD. Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
308 Biocon Limited Biocon Biologics Intl Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
309 Biocon Limited Biocon Biologics Ire Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,012.50 0.00 0.00
310 Biocon Limited Biocon Biologics Ire Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 55.30 0.00 0.00
311 Biocon Limited Biocon Biologics UK PLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,686.00 0.00 0.00
312 Biocon Limited Biocon Biologics UK PLC Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 91.50 0.00 0.00
313 Biocon Limited NeoBiocon FZ LLC Joint Venture Sale of goods or services 55.00 No remarks by the Audit Committee 0.00 0.00 0.00
314 Biocon Limited NeoBiocon FZ LLC Joint Venture Sale of goods or services 55.00 No remarks by the Audit Committee 0.00 0.00 0.00
315 Biocon Limited Bicara Therapeutics Inc. Enterprise in which a director of the Company is a member of board of directors Sale of goods or services 500.00 No remarks by the Audit Committee 0.00 0.00 0.00
316 Biocon Limited Immuneel Therapeutics Private Limited Enterprise in which a director of the Company is a member of board of directors Sale of goods or services 120.00 No remarks by the Audit Committee 0.00 0.00 0.00
317 Biocon Pharma Limited Biocon Biosphere Limited Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 61.10 0.00 0.00
318 Biocon Pharma Limited Biocon FZ LLC Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 61.20 0.00 0.00
319 Biocon Pharma Limited Biocon Pharma Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 32,237.70 0.00 0.00
320 Biocon Pharma Limited Biocon Pharma Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee (13,592.00) 0.00 0.00
321 Biocon Pharma Limited Biocon Pharma UK Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 263.60 0.00 0.00
322 Biocon Pharma Limited Biocon Pharma Malta I Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 368.80 0.00 0.00
323 Biocon Pharma Limited Biocon Pharma Malta I Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 7,518.90 0.00 0.00
324 Biocon Pharma Limited Biocon Generics Inc Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 234.20 0.00 0.00
325 Biocon Pharma Limited Biocon Biologics Ire Ltd Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 280.90 0.00 0.00
326 Biocon Pharma Limited Biocon Pharma UK Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee (539.10) 0.00 0.00
327 Biocon Pharma Limited Biocon Pharma Malta I Ltd Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee (1,242.80) 0.00 0.00
328 Biocon FZ LLC Biocon SDN. BHD. Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
329 Biocon FZ LLC Biocon SDN. BHD. Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
330 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
331 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
332 Biocon Pharma Malta I Ltd Biocon Biologics Ire Ltd Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee (1,199.50) 0.00 0.00
333 Biocon Pharma Malta I Ltd Biocon Biologics Germany Fellow subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,190.40 0.00 0.00
334 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction PLI Reimbursement 0.00 No remarks by the Audit Committee 1,062.40 0.00 0.00
Total value of transaction during the reporting period 9,42,070.30